Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
60.40    0.00 (0.00%)
Bid:
59.00
Ask:
61.80
Spread: 2.80 (4.746%)
Market Cap: £49.19m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Delisting and Compulsory Acqu

29 Jul 2008 07:00

RNS Number : 0658A
Mentor Graphics Corporation
29 July 2008
 



Not for release, publication or distribution, in whole or in part, in, into or from the United StatesCanadaAustralia or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

FOR IMMEDIATE RELEASE

29 JULY 2008

REVISED, RECOMMENDED AND MANDATORY CASH OFFER FOR FLOMERICS GROUP PLC ("FLOMERICS" OR THE "COMPANY") BY MENTOR GRAPHICS CORPORATION ("MENTOR")

Delisting

Mentor announces that it has attained in excess of 75 per cent. of the voting rights attaching to Flomerics Shares, and has taken steps to procure the application by Flomerics for the cancellation of the listing of Flomerics Shares on AIM and the cancellation of trading in Flomerics Shares on AIM. It is anticipated that cancellation of listing and trading will take effect no earlier than 27 August 2008.

This follows the announcement on 10 July 2008 by Mentor that all of the conditions of its Recommended Offer for the entire issued and to be issued ordinary share capital of Flomerics have been satisfied or waived and the Offer is now declared unconditional in all respects.

Following such delisting the liquidity and marketability of any Flomerics Shares that are not acquired by Mentor would be significantly reduced. It is Mentor's intention that, after such cancellation, Flomerics will be re-registered as a private company under the relevant provisions of the Companies Act 1985. 

Compulsory acquisition of outstanding Flomerics Shares.

Mentor also announces that by 3.00 pm on 28 July 2008 it had received valid acceptances in respect of or otherwise contracted to acquire 21,378,423 Flomerics Shares, representing approximately 93.00 per cent of the Flomerics Shares to which the Offer relates.

Accordingly, Mentor announces that compulsory acquisition notices under section 979 of the Companies Act 2006 will be despatched to the holders of Flomerics Shares who have not yet accepted the Offer. The Offer will remain open for acceptance until further notice. Flomerics Shareholders who have not yet accepted the Offer are reminded to complete and return the Forms of Acceptance as soon as possible.

If you have any queries, please contact Computershare on 0870 707 1725 or, if calling from outside the UK, on +44 870 707 1725.

Other 

Terms defined in the Recommended Offer Document shall, unless the context otherwise requires, have the same meanings in this announcement. The term 'acting in concert' shall have the same meaning as in the City Code.

Enquiries:

Mentor Graphics Corporation
 
Ryerson Schwark
Tel: +1 503 685 7000
 
 
Cenkos Securities plc
 
Nicholas Wells
Tel: +44 20 7397 8900
 
 
Bell Pottinger Corporate & Financial
 
David Rydell
 
Olly Scott
Tel: +44 20 7861 3232
 
 
Flomerics Group plc
 
Gary Carter
 
Keith Butcher
Tel: +44 20 8487 3000
 
 
Jefferies International Limited
 
Andres Pieczanski
 
Sarah McNicholas
Tel: +44 20 7029 8000
 
 
Oriel Securities Limited
 
Andrew Edwards
 
Michael Shaw
Tel: +44 20 7710 7600
 
 
Citigate Dewe Rogerson
 
Ginny Pulbrook
 
Seb Hoyle
Tel: +44 20 7638 9571

Cenkos, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Mentor and no one else in connection with the Offer and will not be responsible to anyone other than Mentor for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

Canaccord, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Mentor and no one else in connection with the Offer and will not be responsible to anyone other than Mentor for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

This announcement is not intended to and does not constitute, or form any part of, an offer or an invitation to purchase, subscribe for or otherwise acquire, sell or dispose of any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Offer or otherwise.  The Offer is made solely through the Recommended Offer Document and the Form of Acceptance, which together contain the full terms and conditions of the Offer, including details of how to accept the Offer.  Any acceptance or other response to the Offer should be made only on the basis of the information contained in the Recommended Offer Document and the Form of Acceptance.  The laws of relevant jurisdictions may affect the availability of the Offer to persons not resident in the United Kingdom Persons who are not resident in the United Kingdom, or who are subject to the laws of any jurisdiction other than the United Kingdom, should inform themselves about and observe any applicable legal and regulatory requirements.  The Recommended Offer Document is available for public inspection at the offices of Cenkos. 

The Offer is not being made, directly or indirectly, in or into the United States or by use of mails of, or any means or instrumentality (including, without limitation, facsimile transmission, telephone or internet) of inter-state or foreign commerce of, or any facilities of a national, state or other securities exchange of the United States, nor is it being made directly or indirectly in or into Canada or Australia and the Offer is not capable of acceptance by any such use, means, instrumentality or facilities or from within the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction.  Accordingly, copies of this announcement are not being, will not be and must not be mailed or otherwise forwarded, distributed or sent in, into or from the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction and persons receiving this announcement (including without limitation custodians, nominees and trustees) must not mail, or otherwise forward, distribute or send it in, into or from the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CASDDGDRSGDGGII
Date   Source Headline
20th Apr 202010:01 amRNSUpdate on Results Announcements
16th Apr 202012:48 pmRNSIssue of Equity and Total Voting Rights
2nd Apr 20207:00 amRNSBusiness Update - COVID-19;Notice of Final results
27th Mar 20202:46 pmRNSDirectorate Changes
6th Mar 202012:15 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20203:12 pmRNSHolding(s) in Company
13th Feb 20203:58 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNS2019 Trading update & restructuring activities
7th Feb 20204:44 pmRNSHolding(s) in Company
6th Feb 20206:07 pmRNSHolding(s) in Company
20th Jan 20204:13 pmRNSHolding(s) in Company
15th Jan 20204:38 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSTrading Update - for the year to 31 December 2019
17th Dec 20195:43 pmRNSHolding(s) in Company
5th Dec 20194:41 pmRNSSecond Price Monitoring Extn
5th Dec 20194:35 pmRNSPrice Monitoring Extension
2nd Dec 20194:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20194:35 pmRNSPrice Monitoring Extension
27th Nov 20191:51 pmRNSDirector/PDMR Shareholding
25th Nov 20194:40 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
22nd Nov 20194:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20194:35 pmRNSPrice Monitoring Extension
30th Oct 20199:30 amRNSDirector Share Option Award
28th Oct 20197:00 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading update -nine month period to 30 Sept 2019
30th Sep 20194:10 pmRNSCorrection: Director/PDMR Shareholding
30th Sep 201911:32 amRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSHalf-Year Report - six months ended 30 June 2019
15th Aug 20191:56 pmRNSDirector/PDMR Shareholding
14th Aug 201912:08 pmRNSSecond Price Monitoring Extn
14th Aug 201912:02 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSIssue of Equity and Total Voting Rights (TVR)
18th Jul 201911:29 amRNSDirector/PDMR Shareholding
16th Jul 201912:07 pmRNSSecond Price Monitoring Extn
16th Jul 201912:02 pmRNSPrice Monitoring Extension
12th Jul 20197:00 amRNSGroup Trading Update & Notice of Half-Year results
13th Jun 201911:25 amRNSIssue of Equity and Total Voting Rights
5th Jun 201910:56 amRNSResults of Voting AGM - 5 June 2019 and TVR
5th Jun 20198:46 amRNS2019 Annual General Meeting Statement
16th May 20197:00 amRNSDeferred Consideration and Total Voting Rights
8th May 20191:35 pmRNSAudited Results - Notice of Annual General Meeting
7th May 201911:34 amRNSHolding(s) in Company
17th Apr 20195:21 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSPreliminary results - year ended 31 December 2018
16th Apr 20197:00 amRNSQ1 2019 Trading Update
8th Apr 20195:04 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSHolding(s) in Company
18th Mar 201911:29 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.